| Literature DB >> 31092416 |
Toshio Kokuryo1, Yukihiro Yokoyama2, Junpei Yamaguchi2, Nobuyuki Tsunoda2, Tomoki Ebata2, Masato Nagino2.
Abstract
Cancer is characterized by uncontrolled cell proliferation due to the aberrant activity of various proteins. Cell cycle-related proteins are thought to be important in several functions, such as proliferation, invasion and drug resistance in human malignancies. Never in mitosis gene A-related kinase 2 (NEK2) is a cell cycle-related protein. NEK2 is highly expressed in various tumor types and cancer cell lines. NEK2 expression is correlated with rapid relapse and poor outcome in multiple cancer types. Several researchers have demonstrated that NEK2 inhibition results in anticancer effects against many types of cancers, both in vitro and in vivo. Recent research strongly indicates the advantages of NEK2-targeted therapy for cancer. This review focuses on the current understanding of NEK2 in cancer and the rationale of a xenograft cancer model for cancer treatment. A possible therapeutic strategy, such as inhibitor and nucleic acid medicine targeting of NEK2, is also discussed. CopyrightEntities:
Keywords: Drug delivery system; Inhibitor; NEK2; nucleic acid medicine; review; xenograft cancer model
Mesh:
Substances:
Year: 2019 PMID: 31092416 DOI: 10.21873/anticanres.13341
Source DB: PubMed Journal: Anticancer Res ISSN: 0250-7005 Impact factor: 2.480